Related Experiment Video
Updated: Feb 19, 2026

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
Published on: October 20, 2016
Deletion of Neuropilin 1 from Microglia or Bone Marrow-Derived Macrophages Slows Glioma Progression
Jeremy Tetsuo Miyauchi1, Michael D Caponegro1, Danling Chen1
1Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York.
Abstract:
Glioma-associated microglia and macrophages (GAM), which infiltrate high-grade gilomas, constitute a major cellular component of these lesions. GAM behavior is influenced by tumor-derived cytokines that suppress initial antitumorigenic properties, causing them to support tumor growth and to convert and suppress adaptive immune responses to the tumor. Mice that lack the transmembrane receptor neuropilin-1 (Nrp1), which modulates GAM immune polarization, exhibit a decrease in glioma volumes and neoangiogenesis and an increase in antitumorigenic GAM infiltrate. Here we show that replacing the peripheral macrophage populations of wild-type mice with Nrp1-depleted bone marrow-derived macrophages (BMDM) confers resistance to the development of glioma. This resistance occurred in a similar fashion seen in mice in which all macrophages lacked Nrp1 expression. Tumors had decreased volumes, decreased vascularity, increased CTL infiltrate, and Nrp1-depleted BMDM adopted a more antitumorigenic phenotype relative to wild-type GAMs within the tumors. Mice with Nrp1-deficient microglia and wild-type peripheral macrophages showed resistance to glioma development and had higher microglial infiltrate than mice with wild-type GAMs. Our findings show how manipulating Nrp1 in either peripheral macrophages or microglia reprograms their phenotype and their pathogenic roles in tumor neovascularization and immunosuppression.Significance: This study highlights the proangiogenic receptor neuropilin 1 in macrophages and microglial cells in gliomas as a pivotal modifier of tumor neovascularization and immunosuppression, strengthening emerging evidence of the functional coordination of these two fundamental traits of cancer. Cancer Res; 78(3); 685-94. ©2017 AACR.
Insights
Targeting neuropilin-1 (Nrp1) in glioma-associated microglia and macrophages (GAM) reprogrammed their function, reducing tumor growth and enhancing anti-tumor immunity. Manipulating Nrp1 in these cells offers a potential therapeutic strategy for glioma.
Area of Science:
- Immunology
- Neuro-oncology
- Cancer Biology
Background:
- Glioma-associated microglia and macrophages (GAM) are key cellular components in high-grade gliomas.
- Tumor-derived cytokines reprogram GAM to support tumor growth and suppress anti-tumor immune responses.
- Neuropilin-1 (Nrp1) is a transmembrane receptor that influences GAM immune polarization.
Purpose of the Study:
- To investigate the role of neuropilin-1 (Nrp1) in modulating glioma-associated microglia and macrophages (GAM).
- To determine if manipulating Nrp1 expression in macrophages can confer resistance to glioma development.
Main Methods:
- Generated Nrp1-deficient bone marrow-derived macrophages (BMDM) and bone marrow chimeras.
- Replaced peripheral macrophage populations in wild-type mice with Nrp1-depleted BMDM.
- Analyzed glioma volumes, neoangiogenesis, immune cell infiltration (CTLs), and GAM phenotype in Nrp1-manipulated mice.
Main Results:
- Mice with Nrp1-depleted peripheral macrophages or Nrp1-deficient microglia showed resistance to glioma development.
- Tumors in these mice exhibited decreased volumes, reduced vascularity, and increased cytotoxic T lymphocyte (CTL) infiltration.
- Nrp1-depleted GAM adopted a more anti-tumorigenic phenotype compared to wild-type GAM.
Conclusions:
- Neuropilin-1 (Nrp1) in macrophages and microglial cells is a critical regulator of tumor neovascularization and immunosuppression in gliomas.
- Targeting Nrp1 in GAM can reprogram their function, promoting anti-tumor immunity and inhibiting glioma progression.
- This highlights Nrp1 as a potential therapeutic target for glioma treatment.

